AstraZeneca aims to boost potential supply of COVID-19 vaccine to 2 billion

AstraZeneca, British drugmaker who last month said it could supply one billion doses of coronavirus vaccine that it is developing with scientists at Oxford University has reached a landmark deal to double its production to two billion doses. According to reports, AstraZeneca has signed new agreements with Coalition for Epidemic Preparedness Invations (CEPI), Gavi Vaccine Alliance, and Serum Institute of India (SII), world's largest manufacturer of vaccines by volume, to bring vaccine to low- and middle-income countries and beyond.

Re: When Covid Vaccine Arrives, Need Global Solidarity To Ensure Access For All: UN Chief

" Company today reached a $750m agreement with CEPI and Gavi to support manufacturing, procurement, and distribution of 300 million doses of vaccine, with delivery starting by end of year. In dition, AstraZeneca reached a licensing agreement with SII to supply one billion doses for low and middle-income countries, with a commitment to provide 400 million before end of 2020," company in a press release said on June 4.  

Re: India Will Emerge As A Manufacturing Hub After Vaccine Against COVID Is Developed: DG CSIR

"We are working tirelessly to hour our commitment to ensure bro and equitable access to Oxford’s vaccine across globe and at profit. Today marks an important step in helping us supply hundreds of millions of people around world, including to those in countries with lowest means. I am deeply grateful for everyone’s commitment to this cause and for ir work in bringing this toger in such a short time," said Pascal Soriot, Chief Executive Officer, AstraZeneca.

Re: UN Chief Antonio Guterres Backs Development Of 'people's Vaccine' For Coronavirus

COVID-19 vaccine

Oxford University’s Jenner Institute, working with Oxford Vaccine Group has developed a potential vaccine AZD1222, formerly kwn as ChOx1 nCoV-19. Oxford University recently anunced start of Phase II/III trial of AZD1222 in about 10,000 ult volunteers. new vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold (evirus) virus that causes infections in chimpanzees and contains genetic material of SARS-CoV-2 spike protein. After vaccination, surface spike protein is produced, priming immune system to attack COVID-19 if it later infects body.

Re: Australia To Pledge $207 Million For Vaccine Program In Indo-Pacific Region

(Im Credit: AP)